AstraZeneca invests $2 billion in Summit Therapeutics for new drug development
AstraZeneca announced a $2 billion investment in Summit Therapeutics to advance its pipeline of novel medicines.
Deal structure and upfront payment
The agreement includes an initial payment of $300 million for global rights outside China. Total value could reach $2.6 billion if future milestones are met.
Clinical progress in other areas
Invivyd reported that its experimental antibody showed superior safety compared to approved mRNA vaccines in a trial. Immix Biopharma noted complete remissions in 89% of patients with AL Amyloidosis using its CAR-T therapy.
Long-term results for gene therapy
UniQure found that benefits from its Huntington's gene therapy declined after four years. This decline might complicate the therapy's regulatory review process.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.